Robert Naismith, MD
Neurology · Saint Louis, MONPI 1871519090
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Sanofi at 31.8% of the total. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $1544.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$215K
- Sanofi-aventis U.S. LLC$81K
- Sanofi US Services Inc.$61K
- Amgen$57K
- Genentech USA, Inc.$50K
- E.r. Squibb & Sons, L.L.C.$35K
- plus $176K from 20 others
Across 1,002 payments — averaging $13,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$4.9M
- F. Hoffmann-la Roche AG$2.2M
- Biogen$1.8M
- Novartis$1.6M
- AstraZeneca$925K
- Bristol Myers Squibb$904K
- plus $958K from 9 others
What the payments were for
- Consulting fees$392,46558%
- Speaking & faculty fees$246,90836%
- Travel & lodging$28,8504%
- Food & beverage$8,2241%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 98 | $215,368 |
| Sanofi-aventis U.S. LLC | 28 | $81,398 |
| Sanofi US Services Inc. | 22 | $61,425 |
| Amgen(2 entities) | 48 | $57,125 |
| Genentech USA, Inc. | 36 | $49,929 |
| E.r. Squibb & Sons, L.L.C. | 13 | $34,854 |
| Biogen | 33 | $32,380 |
| H. Lundbeck A S | 7 | $27,345 |
| TG Therapeutics, Inc. | 36 | $25,167 |
| EMD Serono, Inc. | 24 | $19,143 |
| Novartis | 27 | $17,276 |
| AstraZeneca(2 entities) | 28 | $15,739 |
| Bristol Myers Squibb | 13 | $9,453 |
| Celltrion, Inc. | 3 | $6,668 |
| Johnson & Johnson | 4 | $4,575 |
| Greenwich Biosciences, Inc. | 1 | $3,808 |
| Novartis Pharma AG | 1 | $3,300 |
| Genentech, Inc. | 2 | $2,836 |
| Beigene USA, Inc. | 1 | $2,375 |
| F. Hoffmann-la Roche AG | 5 | $2,025 |
| Alkermes, Inc. | 3 | $2,000 |
| Banner Life Sciences, LLC | 1 | $900 |
| Vertex | 1 | $500 |
| GW Pharma Limited | 1 | $450 |
| Cello Health Advantage Inc | 1 | $450 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$676,508 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 15 | $667,568 |
| Kesimpta PenOfatumumab | 54 | $496,663 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 27 | $229,756 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 20 | $215,810 |
| AubagioTeriflunomide | 21 | $193,465 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $115,184 |
| CopaxoneGlatiramer Acetate | 18 | $99,062 |
| Teriflunomide | 52 | $81,449 |
| FingolimodFingolimod Hcl | 39 | $46,821 |
| GlatopaGlatiramer Acetate | 21 | $37,076 |
| MyrbetriqMirabegron | 29 | $16,140 |
| Dalfampridine ErDalfampridine | 31 | $13,848 |
| Baclofen | 91 | $3,807 |
| Gabapentin | 124 | $3,687 |
| Solifenacin Succinate | 26 | $1,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $15,739 | $667,56815 claims |
| SanofiAubagio | $215,368 | $193,46521 claims |
| BiogenAvonex (4 Pack) | $32,380 | $115,18412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 381 neurology providers in Missouri.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
- Jameson HollomanSaint Louis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.